Xencor Inc
Company Information
Industry
Pharmaceutical Preparations
SIC Code
2834
Entity Type
operating
SEC Category
Accelerated filer
State of Incorporation
DE
Business Address
465 N. HALSTEAD ST., PASADENA, CA, 91107
Mailing Address
465 N. HALSTEAD ST., PASADENA, CA, 91107
Phone
626-305-5900
Fiscal Year End
1231
EIN
201622502
Financial Overview
FY2025
$277.92M
Total Liabilities
Recent SEC Filings
| Form Type | Date Filed | Document |
|---|---|---|
| SCHEDULE 13G Passive beneficial ownership (>5%) | March 30, 2026 | View on SEC |
| SCHEDULE 13G/A Passive ownership amendment | March 27, 2026 | View on SEC |
| 4 Insider stock transaction report | March 9, 2026 | View on SEC |
| 4 Insider stock transaction report | March 9, 2026 | View on SEC |
| 4 Insider stock transaction report | March 9, 2026 | View on SEC |
| 8-K Current report of material events | March 9, 2026 | View on SEC |
| 4 Insider stock transaction report | March 9, 2026 | View on SEC |
| 4 Insider stock transaction report | March 4, 2026 | View on SEC |
| 4 Insider stock transaction report | March 4, 2026 | View on SEC |
| 4 Insider stock transaction report | March 4, 2026 | View on SEC |
Annual Reports
10-K
February 25, 2026
- Proprietary XmAb® technology platform enables engineering of enhanced antibody and protein therapeutics.
- Robust pipeline with promising drug candidates like Plamotamab (Phase 2) and XmAb808 (Phase 1).
Material Events
8-K
Legal Issue
March 4, 2026
High Impact
- Xencor is a biotechnology company known for its innovative drug development.
- The company possesses proprietary XmAb® Fc domain technology, critical to drugs like Ultomiris®.
Insider Trading
STRONG SELL
4 insiders
12 recent transactions
View Full Insider Trading Profile
Related Companies
Companies in the same industry (SIC: 2834)
Investor Resources
Learn more about SEC filings and how to research public companies.
What is the SEC?
A plain English guide to the Securities and Exchange Commission
Understanding SEC Filings & CIK
How to navigate SEC filings and Central Index Keys
10-K Annual Reports Explained
Everything you need to know about annual reports
S-1 & F-1 IPO Filings
Understanding IPO registration statements
SEC EDGAR Database Guide
How to use the SEC's free filing database
Important Disclaimer
This AI-generated analysis is for informational purposes only and does not constitute financial or investment advice. Always consult with qualified professionals and conduct your own research before making investment decisions.